Phathom Pharmaceuticals (PHAT) Accumulated Expenses (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Accumulated Expenses of $109.0 million for Q2 2026, up 69.57% year-over-year from $64.3 million in Q2 2025, and up 30.86% quarter-over-quarter from $83.3 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Accumulated Expenses (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Accumulated Expenses for 9 consecutive years, with $109.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Accumulated Expenses rose 69.57% year-over-year to $109.0 million; the TTM figure through Jun 2026 stood at $109.0 million (up 69.57% YoY), while the FY2025 annual figure was $89.8 million, up 68.75% from the prior year.
- Accumulated Expenses improved to $109.0 million in Q2 2026 per PHAT's latest filing, from $83.3 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $109.0 million in Q2 2026 and bottomed at $7.6 million in Q1 2022.
- Historically, Accumulated Expenses has averaged $38.4 million across 5 years, with a median of $22.2 million in 2023.
- Annual changes were most pronounced in 2023 — Accumulated Expenses grew 1.25% — and 2024, when it soared 209.54%.
- Phathom Pharmaceuticals' Accumulated Expenses stood at $14.7 million in 2022, then increased by 17.16% to $17.2 million in 2023, then jumped by 209.54% to $53.2 million in 2024, then soared by 68.75% to $89.8 million in 2025, then grew by 21.37% to $109.0 million in 2026.
- Business Quant data shows PHAT's Accumulated Expenses at $109.0 million in Q2 2026, $83.3 million in Q1 2026, and $89.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 109.03 Mn |
| Mar 31, 2026 | 83.32 Mn |
| Dec 31, 2025 | 1.83 Mn |
| Sep 30, 2025 | 65.35 Mn |
| Jun 30, 2025 | 18.71 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 53.23 Mn |
| Sep 30, 2024 | 35.76 Mn |
| Jun 30, 2024 | 1.43 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 1.15 Mn |
| Sep 30, 2023 | 13.46 Mn |
| Jun 30, 2023 | 927,000.00 |
| Mar 31, 2023 | 3.49 Mn |
| Dec 31, 2022 | 8.45 Mn |
| Sep 30, 2022 | 686,000.00 |
| Jun 30, 2022 | 13.78 Mn |
| Mar 31, 2022 | 7.57 Mn |
| Dec 31, 2021 | 11.41 Mn |
| Sep 30, 2021 | 214,000.00 |